Elutia (NASDAQ:ELUT) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Elutia (NASDAQ:ELUT) issued its earnings results on Thursday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02), FiscalAI reports. The firm had revenue of $3.11 million for the quarter, compared to analyst estimates of $3.00 million.

Here are the key takeaways from Elutia’s conference call:

• Elutia said its FDA review of NXT-41 is progressing well, giving management increased confidence in the planned NXT-41X submission and expected timeline of NXT-41 clearance in Q4 2026 and NXT-41X in the first half of 2027.
• The company brought its automated manufacturing platform online during the quarter, and believes it can support 80%+ gross margins at scale while helping keep pricing competitive.
• Management reiterated the large opportunity in breast reconstruction, citing a $1.5 billion U.S. market with high infection rates and limited innovation in current standard of care. They said surgeon feedback supports a concentrated commercial launch focused on a few hundred high-volume hospitals.
• Elutia ended the quarter with $36.5 million in cash and escrow, which management believes is sufficient to fund planned regulatory and operational milestones.
• The company remains active on strategic transactions, including the previously announced SimpliDerm divestiture and newly disclosed inbound interest in its cardiovascular product line, both of which could further strengthen the balance sheet and sharpen focus on NXT-41X.

Elutia Price Performance

ELUT stock opened at $1.04 on Friday. The company has a fifty day moving average price of $1.09 and a 200 day moving average price of $0.92. Elutia has a 12 month low of $0.50 and a 12 month high of $2.64. The company has a market cap of $44.49 million, a price-to-earnings ratio of 1.27 and a beta of 0.75.

Institutional Trading of Elutia

Several institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC purchased a new position in Elutia during the 1st quarter worth $48,000. XTX Topco Ltd purchased a new position in Elutia during the 2nd quarter worth $28,000. Deerfield Management Company L.P. purchased a new position in Elutia during the 3rd quarter worth $1,221,000. Virtu Financial LLC purchased a new position in Elutia during the 3rd quarter worth $26,000. Finally, Citadel Advisors LLC purchased a new position in Elutia during the 3rd quarter worth $50,000. Hedge funds and other institutional investors own 74.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ELUT. Wall Street Zen upgraded shares of Elutia from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. Weiss Ratings upgraded shares of Elutia from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, April 10th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $6.00.

About Elutia

Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.

The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.